PRESS RELEASE published on 09/12/2024 at 13:09, 6 days 14 hours ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 06/17/2024 at 07:05, 3 months 1 day ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
BRIEF published on 06/17/2024 at 07:05, 3 months 1 day ago Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers Sanofi Innate Pharma SAR443579 Leukemia Blood Cancer
PRESS RELEASE published on 06/17/2024 at 07:00, 3 months 1 day ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 3 months 1 day ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 3 months 21 days ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
BRIEF published on 05/28/2024 at 07:05, 3 months 21 days ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
PRESS RELEASE published on 05/28/2024 at 07:00, 3 months 21 days ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 3 months 26 days ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
BRIEF published on 05/23/2024 at 22:05, 3 months 26 days ago Results of the Combined General Meeting of Innate Pharma Voting Results Supervisory Board General Assembly Innate Pharma
Published on 09/18/2024 at 23:10, 4 hours 12 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 4 hours 22 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 6 hours 7 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 6 hours 22 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 10 hours 52 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 8 hours 10 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 8 hours 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 8 hours 50 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 9 hours 8 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 10 hours ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 8 hours 36 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 8 hours 36 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 9 hours 42 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.